PRAX (Praxis Precision Medicines) Valuation Rank


PRAX Praxis Precision Medicines Inc PRAX
38 GF Score
Price $350.56
GF Value $31.07
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is Praxis Precision Medicines Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Praxis Precision Medicines Valuation Rank Related Terms

PRAX
38GF Score
Praxis Precision Medicines Inc PRAX
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Praxis Precision Medicines (PRAX) Overvalued in 2026?

Based on GuruFocus' analysis, Praxis Precision Medicines stock appears to be overvalued. The current stock price of $350.56 is trading 1028.3% above its estimated GF Value™ of $31.07. GuruFocus considers Praxis Precision Medicines to be Significantly Overvalued.

Key valuation signals for PRAX:

  • Valuation Rank:
  • GF Value™: $31.07 vs. price of $350.56 (1028.3% above fair value)
  • GF Score™: 38/100 with 3 warning signs

No single metric tells the full story. See the PRAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Praxis Precision Medicines Business Description

Address 99 High Street, 30th Floor, Boston, MA, USA, 02110
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.
38GF Score

Get the complete analysis for PRAX

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$350.56
Price
$31.07
GF Value